Holen Sie sich die Stockscreener-App
9.78
2.41%
0.23
Vorhandelsmarkt:
9.69
-0.09
-0.92%
Schlusskurs vom Vortag:
$9.55
Offen:
$9.41
24-Stunden-Volumen:
28.92M
Relative Volume:
0.90
Marktkapitalisierung:
$9.63B
Einnahmen:
$1.31M
Nettoeinkommen (Verlust:
$-597.65M
KGV:
-10.08
EPS:
-0.97
Netto-Cashflow:
$-425.62M
1W Leistung:
+12.41%
1M Leistung:
+64.37%
6M Leistung:
+317.95%
1J Leistung:
+241.96%
1-Tages-Spanne:
$8.83
$9.80
1-Wochen-Bereich:
$8.83
$12.43
52-Wochen-Spanne:
$1.83
$12.43
Immunitybio Inc Stock (IBRX) Company Profile
Firmenname
Immunitybio Inc
Sektor
Branche
Telefon
(844) 696-5235
Adresse
3530 JOHN HOPKINS COURT, SAN DIEGO
Compare IBRX vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
IBRX
Immunitybio Inc
|
9.78 | 9.41B | 1.31M | -597.65M | -425.62M | -0.97 |
|
VRTX
Vertex Pharmaceuticals Inc
|
496.83 | 121.97B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
781.67 | 81.49B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
766.92 | 47.74B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
332.92 | 43.93B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
316.99 | 35.67B | 4.98B | 69.60M | 525.67M | 0.5198 |
Immunitybio Inc Stock (IBRX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-05-20 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2025-03-06 | Eingeleitet | H.C. Wainwright | Buy |
| 2025-01-10 | Eingeleitet | BTIG Research | Buy |
| 2023-05-12 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2022-08-03 | Eingeleitet | Jefferies | Buy |
Immunitybio Inc Aktie (IBRX) Neueste Nachrichten
Special Edition: Why Can’t We Cure Cancer? A National Conversation | Full CUOMO Show 2/27 - ImmunityBio
ImmunityBio Stock Pre-Market (+6.5%): Phase 2 Trial Enrollment Completed Early - Trefis
ImmunityBio (NASDAQ:IBRX) Shares Up 2.4%Still a Buy? - MarketBeat
Key facts: ImmunityBio completes Phase 2 trial enrollment; conference call set - TradingView
Promising Biotech Stocks To ConsiderFebruary 27th - MarketBeat
ImmunityBio to Provide a Business Update and Review Financial Results for FY 2025 on Tuesday, March 3, 2026 - BioSpace
IBRX Stock Ignites Retail Frenzy Ahead Of Founder’s Prime-Time TV Blitz — Traders Bets On Saudi Funding And Trump Tailwinds - Stocktwits
ImmunityBio Trial Progress Puts Anktiva’s Global Cancer Potential in Focus - Yahoo Finance
IBRX Stock Price, Forecast & Analysis | IMMUNITYBIO INC (NASDAQ:IBRX) - ChartMill
ImmunityBio (NASDAQ:IBRX) Director Sells $900,750.00 in Stock - MarketBeat
Simon, director, sells ImmunityBio (IBRX) shares worth $900k - Investing.com
Assessing ImmunityBio (IBRX) Valuation After Trial Progress And Strong Anktiva Commercial Momentum - Yahoo Finance
ImmunityBio Grapples with Allegations as Stock Tumbles - timothysykes.com
ImmunityBio (IBRX) loses 17% to profit-taking after intra-day high - MSN
ImmunityBio Investors Rally Behind Cancer Trial Milestone - Benzinga
IBRX Stock Reverses Pre-Market Gains After ANKTIVA Combo Shows Stronger Bladder Cancer Responses – Retail Sees Consolidation Before Next Leg Up - Stocktwits
ImmunityBio completes enrollment in bladder cancer trial - Investing.com
ImmunityBio completes enrollment in bladder cancer trial By Investing.com - Investing.com UK
ImmunityBio Completes Enrollment in Pivotal Randomized Trial Evaluating ANKTIVA® Plus BCG Versus BCG Alone in BCG-Naïve Non-Muscle Invasive Bladder Cancer Carcinoma In Situ - Business Wire
ImmunityBio (IBRX) Loses 17% to Profit-Taking After Intra-Day High - Finviz
Patrick Soon-Shiong Reaffirms Control Over ImmunityBio with 66.3% Stake - Intellectia AI
IMMUNITYBIO, INC. (IBRX) Stock, Price, News, Quotes, Forecast and Insights - MSN
ImmunityBio Founder Reaffirms Grip As Stock Plunges In Worst Selloff Since 2024 After Massive Rally - Stocktwits
ImmunityBio Stock Is Up 18% This Week: Here’s What Global ANKTIVA Approvals Mean - TIKR.com
ImmunityBio (NASDAQ:IBRX) Trading Down 17.4% on Insider Selling - MarketBeat
Dr. Patrick Soon-Shiong will participate as a speaker at the "Cancer 2035: A Roadmap for the Future" - Oncodaily
Why ImmunityBio Stock Is Soaring Today - AOL.com
Biotech Stocks To Follow TodayFebruary 25th - MarketBeat
ImmunityBio Supersedes Expectations With Fivefold Revenue IncreaseImmunityBio (NASDAQ:IBRX) - Benzinga
ImmunityBio Stock (IBRX) Opinions on Saudi Launch and EU Approval - Quiver Quantitative
ImmunityBio (NASDAQ:IBRX) Trading Down 8.8% Following Insider Selling - MarketBeat
ImmunityBio Faces Intense Scrutiny as Legal Concerns Mount - timothysykes.com
ImmunityBio's 471% Stock Rally Could Enter Next Round If Shorts Capitulate - Finviz
ImmunityBio’s 471% Surge Could Trigger A Massive Short SqueezeImmunityBio (NASDAQ:IBRX) - Benzinga
ImmunityBio Shares Surge on Stellar Revenue Growth and Regulatory Milestones - AD HOC NEWS
ImmunityBio Surges as Anktiva Drives 671% Revenue Growth - Tokenist
ImmunityBio: Disconnect Between Clinical Progress And Stock Performance (NASDAQ:IBRX) - Seeking Alpha
ImmunityBio stock jumps again in premarket as ANKTIVA sales surge puts IBRX in focus - TechStock²
Q1 Earnings Estimate for ImmunityBio Issued By HC Wainwright - MarketBeat
ImmunityBio (IBRX) Reports 700% Revenue Surge Driven by Rapid ANKTIVA Adoption - Finviz
ImmunityBio (IBRX) Revenue Ramp To US$38 Million Tests Profitability Optimism - simplywall.st
IBRX ImmunityBio NASDAQ pre-market up on Q4 beat 25 Feb 2026: ANKTIVA outlook - Meyka
ImmunityBio (IBRX) Skyrockets as Anktiva Propels 671% Revenue Jump - Insider Monkey
ImmunityBio, Inc. (NASDAQ:IBRX) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Insider Selling: ImmunityBio (NASDAQ:IBRX) Director Sells $250,000.00 in Stock - MarketBeat
ImmunityBio, Inc. (IBRX): Harnessing a 407% Revenue Growth with a Promising 28% Upside Potential - DirectorsTalk Interviews
Selecky of Immunitybio sells $250,000 in shares - Investing.com
Simon, Barry J. sells ImmunityBio (IBRX) shares worth $1.78 million - Investing.com
IBRX Stock Rallies Into Trump’s Big SOTU Night — Here’s What Traders Think Could Fuel The Next Move - Stocktwits
Simon, Barry J. sells ImmunityBio (IBRX) shares worth $1.78 million By Investing.com - Investing.com Nigeria
Selecky of Immunitybio sells $250,000 in shares By Investing.com - Investing.com Nigeria
Finanzdaten der Immunitybio Inc-Aktie (IBRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
Immunitybio Inc-Aktie (IBRX) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Selecky Christobel | Director |
Feb 23 '26 |
Option Exercise |
2.98 |
25,000 |
74,500 |
25,000 |
| Selecky Christobel | Director |
Feb 23 '26 |
Sale |
10.00 |
25,000 |
250,000 |
0 |
| Sachs David C. | Chief Financial Officer |
Feb 22 '26 |
Option Exercise |
0.00 |
40,650 |
0 |
320,825 |
| SOON-SHIONG PATRICK | See remarks |
Feb 22 '26 |
Option Exercise |
0.00 |
114,329 |
0 |
29,816,081 |
| LAUER REGAN J | Chief Accounting Officer |
Feb 22 '26 |
Option Exercise |
0.00 |
4,065 |
0 |
117,548 |
| Adcock Richard | CEO & President |
Feb 22 '26 |
Option Exercise |
0.00 |
152,439 |
0 |
637,904 |
| Simon Barry J. | Director |
Feb 22 '26 |
Option Exercise |
0.00 |
15,243 |
0 |
3,096,847 |
| Simon Barry J. | Director |
Feb 23 '26 |
Sale |
10.25 |
165,000 |
1,691,102 |
2,925,821 |
| Simon Barry J. | Director |
Feb 20 '26 |
Sale |
9.25 |
10,000 |
92,500 |
3,081,604 |
1.18%
0.45%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):